Rare and unusual adverse thrombotic events and thrombocytopenia may be associated with COVID-19 vaccines from AstraZeneca and Johnson & Johnson (J&J), so called vaccine-associated immune thrombotic thrombocytopenia (VITT). VITT resembles autoimmune heparin-induced thrombocytopenia, a well-known prothrombotic disorder caused by platelet-activating antibodies that recognize multimolecular complexes between cationic platelet factor 4 and anionic heparin or other triggers. Patients may develop severe headache, abdominal pain, leg pain, shortness of breath, petechiae, or new or easy bruising, etc. within three weeks after vaccination. As with heparin-induced thrombocytopenia, the administration of the anticoagulant heparin should be avoided in patients with potential VITT, unless heparin-induced thrombocytopenia testing is negative. Non-heparin anticoagulants and high-dose intravenous immune globulin should be considered in treatment of patients with VITT. Consultation with hematology specialists is strongly recommended. Both of the vaccines contain replication-incompetent adenoviral vectors (human [Ad26.COV2. S] for J&J and chimpanzee [ChAdOx1] for AstraZeneca) that encode the spike glycoprotein of SARS-CoV-2, the virus that causes COVID-19. Source: https://emergency.cdc.gov/; https://www.nejm.org/
Both clinician-rated and patient-reported outcomes suggested that mindfulness-based stress reduction (MBSR) was well-tolerated with comparable…
The number of individuals with high blood pressure (BP) is increasing worldwide. The trajectory of…
A single combined measure of high-sensitivity C-reactive protein (CRP), low-density lipoprotein (LDL) cholesterol, and lipoprotein(a)…
A French multicenter, open label, randomized, noninferiority trial suggested that interruption of long-term beta-blocker treatment…
A US prospective cohort study demonstrated that replacement of animal fat with an equivalent amount…
An ongoing UK national prospective program shows remission of type 2 diabetes (T2D) outside of…
This website uses cookies.